Rukobia (fostemsavir) Patient Assistance Program
Don’t let the high cost of brand HIV attachment inhibitor disrupt your multidrug-resistant HIV treatment. We help eligible patients access Rukobia (fostemsavir extended-release tablets) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Rukobia (fostemsavir) is FDA-approved in combination with other antiretroviral(s) for treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection who are failing their current regimen. First-in-class HIV attachment inhibitor — binds gp120 to prevent HIV attachment to CD4+ T cells. Prodrug of temsavir.
- Without assistance, Rukobia costs commonly run approximately $8,000+ per month.
- Through AffordMyPrescriptions, qualifying patients can access Rukobia for a flat $69.95 per month.
- Other HIV therapies for multidrug-resistant HIV: Sunlenca (lenacapavir long-acting SC every 6 months — HIV-1 capsid inhibitor), Trogarzo (ibalizumab-uiyk IV every 2 weeks — post-attachment inhibitor targeting CD4). Standard HIV therapy: Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide — most-prescribed HIV STR), Dovato (dolutegravir/lamivudine — 2-drug STR), Triumeq, and many other options including generics (Atripla generic, Complera generic, Symfi). Long-acting Cabenuva (cabotegravir + rilpivirine IM). Comprehensive resistance testing informs treatment selection. Ryan White HIV/AIDS Program.
What is Rukobia Prescription Assistance Program?
The Rukobia Patient Assistance Program helps eligible patients access this HIV attachment inhibitor at little or no cost when meeting income, insurance, and clinical criteria.
At AffordMyPrescriptions, our Patient Advocates handle the entire Rukobia PAP enrollment for a flat $69.95 per month — so you never face a gap in Rukobia HIV therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Rukobia enrollment — so you never face a gap in your multidrug-resistant HIV treatment.
Pharmacy Price Comparison
- Without assistance, Rukobia costs thousands per month at specialty pharmacies. A Patient Assistance Program can offset costs if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Ryan White HIV/AIDS Program | programs | State ADAP funding |
| Specialty pharmacy | ~$8,000/mo | Save substantially |
| Walgreens Specialty | ~$8,500/mo | Save substantially |
| CVS Specialty | ~$8,800/mo | Save substantially |
| 340B-eligible institution | ~$6,500/mo | Save substantially |
| Sunlenca (alt MDR HIV) | ~$40,000/yr | Alt long-acting for MDR HIV |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Rukobia — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Rukobia Prescription Program?
The Rukobia Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. Multidrug-resistant HIV requires HIV specialty care and comprehensive resistance testing. Ryan White HIV/AIDS Program and state ADAP fund HIV treatment.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Rukobia assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Rukobia is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Rukobia:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $8,000+ per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Rukobia assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Rukobia Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Rukobia:
Rukobia is the first-in-class HIV attachment inhibitor for heavily treatment-experienced adults with multidrug-resistant HIV — binds gp120 to prevent HIV attachment to CD4+ T cells. Novel mechanism complementary to other HIV therapy classes.
How It Works:
HIV-1 infection with multidrug resistance is a serious challenge — patients on failing regimens accumulate resistance mutations that limit remaining active drug options. Historically, heavily treatment-experienced patients with resistance to multiple drug classes had very few viable regimen options. Newer agents targeting novel mechanisms (attachment inhibitors, capsid inhibitors, post-attachment inhibitors) expand options. Temsavir (active form of fostemsavir prodrug) binds directly to HIV-1 gp120 glycoprotein — prevents attachment of gp120 to CD4 on host T cells, the first step in HIV entry. Prevents infection of new cells. Different mechanism from standard NNRTIs, NRTIs, PIs, INSTIs, and gp41-targeting entry inhibitor enfuvirtide. Complementary to other HIV therapy classes. Retains activity against HIV strains resistant to standard antiretrovirals.
Form and Use:
Rukobia 600 mg extended-release tablets. 600 mg twice daily with or without food. Combined with optimized background HIV regimen. HIV specialist prescribing.
Generic Availability:
No generic Rukobia. Other therapies for multidrug-resistant HIV: Sunlenca (lenacapavir — long-acting SC every 6 months; HIV-1 capsid inhibitor — brand), Trogarzo (ibalizumab-uiyk — IV every 2 weeks; post-attachment inhibitor targeting CD4 — brand). Cabenuva (cabotegravir + rilpivirine — long-acting IM for virologically suppressed HIV, not multidrug-resistant). Standard HIV therapy (many options): Biktarvy (most-prescribed STR), Dovato (2-drug STR), Triumeq, Genvoya, Odefsey, Symtuza, and older generic STRs (Atripla generic, Complera generic, Symfi). Individual generic components. Ryan White HIV/AIDS Program funds HIV treatment; state ADAP. HIV Medicine Association and HIV.gov resources.
Warnings:
Immune reconstitution inflammatory syndrome (IRIS — can unmask underlying infections upon initiation), QT prolongation (dose-dependent — caution with concomitant QT-prolonging medications), hepatotoxicity (monitor LFTs; caution in HBV/HCV co-infection), embryo-fetal considerations, drug interactions (CYP3A4 substrate, P-gp interactions — check all concomitant medications; rifampin contraindicated — strong CYP3A4 inducer). Other: nausea, headache, diarrhea, fatigue. Coordinate with HIV specialist for entire regimen. Comprehensive resistance testing essential for treatment selection.
FAQ (Frequently Asked Questions)
How much does Rukobia cost without insurance?
$8,000+ per month at specialty pharmacies. Sunlenca (alternative for multidrug-resistant HIV — long-acting) similarly expensive per treatment cycle. Ryan White HIV/AIDS Program and state ADAP major resources for HIV treatment access.
How is Rukobia different from other HIV therapies?
Rukobia (fostemsavir) is a first-in-class HIV attachment inhibitor — binds HIV-1 gp120 glycoprotein to prevent attachment to CD4 T cells. Novel mechanism distinct from NNRTIs, NRTIs, PIs, INSTIs, and gp41-targeting entry inhibitor enfuvirtide. Retains activity against HIV strains resistant to standard antiretrovirals. For heavily treatment-experienced patients with multidrug-resistant HIV.
How is Rukobia different from Sunlenca?
Both target novel HIV mechanisms for multidrug-resistant HIV. Rukobia (fostemsavir): HIV attachment inhibitor, oral twice daily. Sunlenca (lenacapavir): HIV capsid inhibitor, subcutaneous injection every 6 months. Different mechanisms — complementary options for multidrug-resistant HIV. Discuss with HIV specialist.
How is Rukobia different from Trogarzo?
Both address multidrug-resistant HIV via entry-related mechanisms. Rukobia binds HIV gp120 (attachment inhibitor). Trogarzo (ibalizumab-uiyk) binds CD4 on host cells (post-attachment inhibitor). Different targets but both block early HIV entry steps. Different administration: Rukobia oral, Trogarzo IV every 2 weeks.
Who is appropriate for Rukobia?
Heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing current regimen. Requires HIV specialist evaluation, resistance testing, and treatment history review. Combined with optimized background regimen (partner drugs based on resistance profile).
Take Control of Your Medication Costs
Novel HIV attachment inhibition for multidrug-resistant HIV can restore virologic suppression. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.